Rockville, Maryland (PRWEB) May 21, 2014
This new method, marketed under the S-PLEX brand, is 1000 times more sensitive than existing ELISA technologies, and enables measurements of biomarkers that were previously not possible. The results reported at the AAPS conference demonstrate detection limits well below 1 fg/mL, which rivals any immunoassay available today.
“We are extremely pleased to offer these new, ultra-sensitive assays,” said Jacob Wohlstadter, President and Chief Executive Officer of MSD. “S-PLEX assays will enable our customers to study biomarkers that were previously unmeasurable, giving researchers new tools to solve problems from basic science to clinical medicine.”
S-PLEX assays use MSD’s proven electrochemiluminescence technology, which has been widely adopted by pharmaceutical companies, universities and clinical laboratories throughout the world. Proprietary enhancements to MSD’s established platform provide S-PLEX assays with improved sensitivity and specificity, while retaining the simple, robust methods and multiplex capability of MSD’s existing products.
“Other methods for sensitive assays require purchasing dedicated instrumentation, and resort to exotic techniques to reach low detection limits,” said Dr. James Wilbur, General Manager. “S-PLEX assays use our existing instrumentation, which means that MSD customers will get ultra-sensitive assays without the need to purchase additional instruments or validate a new technology.”
MSD will immediately offer the S-PLEX products as an assay development service, in which customers can select from a menu of 31 biomarker assays in development or other biomarkers of their choosing. In the near future, MSD will offer S-PLEX assays in ready-to-use kits that will be fully compatible with its current SECTOR® and QuickPlex® lines of instruments.
For more information on S-PLEX immunoassays, call Customer Service at 1-240-314-2795; email customerservice(at)mesoscale(dot)com; or visit http://www.mesoscale.com/S-PLEX.
About Meso Scale Diagnostics, LLC.
Meso Scale Diagnostics, LLC., based in Rockville, Maryland, develops, manufactures, and markets instruments and assays for array-based biological measurements for research use in life sciences and for biodefense applications. MSD is the world’s leading provider of highly sensitive multiplex immunoassays. More information about MSD and its products can be found at http://www.mesoscale.com.